-
CDE Includes Double-Crane’s Hydroxocobalamine and Sanofi Genzyme’s Fitusiran in Rare Disease Care Plan
•
China’s Center for Drug Evaluation (CDE) has announced the inclusion of China Resources Double-Crane Pharmaceutical Co., Ltd’s (SHA: 600062) hydroxocobalamine and Sanofi (NASDAQ: SNY) Genzyme’s fitusiran in its patient-centered rare disease drug development pilot program, known as the Care Plan. Hydroxocobalamine for Metabolic Disorders in Children with MMAHydroxocobalamine, also referred…
-
Sanofi’s Sarclisa Receives CHMP Recommendation for Newly Diagnosed Multiple Myeloma
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with…
-
Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund
•
Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic investment totaling USD 20 million from global pharmaceutical leader Sanofi (NASDAQ: SNY) and Perceptive Xontogeny Venture Fund (PXV Fund I). This investment is a significant component of Zucara’s USD 20 million Series B financing round,…
-
Sanofi and Cathay Capital Forge Partnership to Boost Sino-French Pharmaceutical Cooperation
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has signed a partnership deal with Cathay Capital, a global private equity and venture capital investment firm, at the 7th China International Import Expo (CIIE). This collaboration aims to deepen their existing long-term cooperation and serves as a positive step towards promoting Sino-French cooperation…
-
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
-
Sanofi’s Dupixent Gains EMA Approval for Eosinophilic Esophagitis in Children
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from the European Medicines Agency (EMA) for its drug Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged one to 11 years who weigh at least 15 kg. The approval covers patients who are inadequately…
-
NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status
•
The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for generic quality consistency evaluation (GQCE) work, marking a significant step in the regulation of generic drug quality in China. Concurrently, the NMPA has also announced the first batch of reference drugs that have been stripped…
-
Sanofi’s Dupixent Demonstrates Positive Results in Phase III Study for Chronic Urticaria
•
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced the presentation of new data from the Phase III LIBERTY-CUPID Study C for its drug Dupixent (dupilumab) in the treatment of chronic spontaneous urticaria (CSU) at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 annual meeting. The LIBERTY-CUPID Study…
-
Thermo Fisher Faces FDA Scrutiny Over Syringe Air Bubble Protocols at North Carolina Plant
•
Thermo Fisher Scientific’s (NYSE: TMO) Greenville, North Carolina, facility has come under scrutiny after a US Food and Drug Administration (FDA) inspection revealed certain production procedure issues, including the monitoring and measurement of air bubbles within syringes, according to a Form 483 document obtained by Reuters. The inspection was part…
-
Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
•
Sanofi (EPA: SAN; NASDAQ: SNY) has initiated negotiations with private equity firm CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business, marking a significant milestone in the French pharmaceutical giant’s strategic realignment. While no decision has been finalized, Sanofi will provide further updates…
-
Sanofi’s Consumer Health Unit Attracts Binding Offers, Potential EUR 15 Billion Deal
•
French pharmaceutical giant Sanofi S.A. (EPA: SAN; NASDAQ: SNY) has reportedly received multiple binding offers for its consumer health care (CHC) division, from private equity firms Clayton Dubilier & Rice and PAI Partners, according to sources cited by Bloomberg. The potential deal could value the business at up to EUR…
-
Sanofi’s Sarclisa Secures FDA Approval for First-Line Multiple Myeloma Treatment
•
Sanofi (EPA: SAN; NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted a third indication for its CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM). The new approval allows for the first-line use of Sarclisa in combination with standard-of-care treatments, specifically bortezomib,…
-
Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med
•
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant licensing agreement with US biotechnology firm RadioMedix Inc. and French company Orano Med, securing global rights to a radioligand therapy (RLT). The agreement centers on AlphaMexi (212Pb-DOTAMTATE), a targeted alpha therapy (TAT) that utilizes a…
-
Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives
•
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from two Phase III clinical trials for its drug Dupixent (dupilumab), indicating its potential for two distinct indications. The first trial, ADEPT, concentrated on the treatment of the rare skin condition bullous pemphigoid (BP), while the…
-
Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns
•
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of its flu vaccines in China following concerns over declining potency identified during routine batch checks. According to FiercePharma.com, which cites an email from a Sanofi spokesperson, the suspension will affect supplies of both Vaxigrip and…
-
Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions
•
Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results for the second quarter of 2024, demonstrating a robust year-on-year growth of 10.2% in global net sales, reaching €10.745 billion (USD 11.64 billion) in constant currency terms. This growth was driven by the company’s Pharma…
-
Sanofi to Bolster Hyderabad Facility with $437M Investment, Eyeing Tech Upgrades
•
Sanofi (NASDAQ: SNY; EPA: SAN), a leading French multinational pharmaceutical company, has announced plans to significantly expand its global capacity center (GCC) in Hyderabad, India. The company intends to invest EUR 400 million, equivalent to approximately USD 437 million, over a six-year period. This expansion will create an additional 1,600…
-
Sanofi’s RSV Preventative Therapy Beyfortus Launches in China
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus (nirsevimab), a preventative therapy for Respiratory Syncytial Virus (RSV), in China. Nirsevimab, a long-acting monoclonal antibody (mAb), is the first and only RSV preventative therapy in China that covers a wide range of infants, including…
-
Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit
•
Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer healthcare division, according to a Bloomberg report citing people familiar with the matter. The French pharmaceutical giant is anticipating initial bids by mid-July. Among the parties showing the most interest are Advent International, a U.S.…
-
Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets
•
Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with U.S.-based Belharra Therapeutics, a chemoproteomics company focused on the development of small-molecule cancer drugs targeting high-value, elusive drug targets. As per the agreement, Belharra will utilize its non-covalent chemoproteomics platform to screen for hits against…
-
Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with artificial intelligence-based technologies provided by Bluecrux, a consulting and technology firm based in Belgium. Bluecrux’s solution consolidates all of Sanofi’s data systems into a unified model, enabling comprehensive end-to-end visibility across the company’s supply chain.…
-
Sanofi’s Sarclisa Receives FDA Priority Review for Newly Diagnosed Multiple Myeloma Treatment
•
Sanofi plc (NYSE: SNY), a leading pharmaceutical company based in France, has announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to a supplemental approval filing for its drug Sarclisa (isatuximab). The priority status is in recognition of the molecule’s potential use in treating adult…
-
Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion
•
France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ: NVAX), aiming to enhance its immunization portfolio. Under the agreement, Sanofi will gain access to Novavax’s Matrix-M adjuvant and secure exclusive rights to combine its influenza vaccines with Novavax’s SARS-CoV-2 vaccine. Sanofi will also co-commercialize…
-
AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial
•
AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing its JAK inhibitor Rinvoq (upadacitinib) with Sanofi’s (NASDAQ: SNY) interleukin blocker Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis. The trial demonstrated that Rinvoq was superior in improving eczema area and severity as well as…
-
Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches
•
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to €10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to €7.76…
-
Sanofi’s Rilzabrutinib Meets Primary Endpoint in Phase III ITP Trial
•
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its Phase III trial for rilzabrutinib, a potential best-in-class BTK inhibitor, has successfully met its primary endpoint of durable platelet response in patients with immune thrombocytopenia (ITP). The trial also produced positive results in key secondary endpoints and did not raise…
-
Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers
•
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a patient in the second part of a Phase I/II clinical trial for the trifunctional NK cell engager SAR443579, targeting blood cancers. The announcement was made by fellow French biotechnology company Innate Pharma (NASDAQ: IPHA) this…
-
Sanofi Explores Sale of Amunix Pharmaceuticals as It Shifts Focus to Immunology
•
Sanofi (NASDAQ: SNY), the France-based pharmaceutical giant, is reportedly in talks with potential buyers for Amunix Pharmaceuticals, an immuno-oncology company it acquired in 2021, according to Endpoints News. This move aligns with Sanofi’s 2023 earnings report, which outlined plans to shift resources away from oncology to bolster its immunology pipeline,…
-
Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation
•
France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics (NASDAQ: NRIX), a leader in targeted protein degradation, focusing on the drug target STAT6 for type 2 inflammation. The partners anticipate identifying a clinical candidate within the next year. As part of the collaboration, Nurix…
-
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will result in the layoff of up to 680 staff members across its Swiss and US development teams. This move, reported by Endpoints News, comes on the heels of similar announcements from industry peers Bayer (ETR:…
-
Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort
•
Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that will result in significant layoffs and corporate restructuring, according to an internal communication dated April 4, 2024. The strategic shift, led by Sanofi’s R&D head Dr. Houman Ashrafian, follows an extensive review and consultation with…
-
Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools
•
Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China this week to launch KiDS (Kids & Diabetes in Schools), a program aimed at enhancing health literacy in school environments. Charmeil, who previously served as Sanofi’s China region head, also spoke to local media platform…
-
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first quarter of 2024. Despite expectations that its top-selling interleukin blocker Dupixent (dupilumab) will face challenges from a co-pay assistance program in the first quarter, the company projects that the drug’s sales will reach EUR 13…
-
Sanofi’s Amlitelimab Shows Promising Phase IIb Results in Atopic Dermatitis, Potential for 12-Week Dosing
•
Sanofi (NASDAQ: SNY) announced this week promising results from a Phase IIb study of its OX40-ligand blocker, amlitelimab, in patients with moderate to severe atopic dermatitis. The study focused on participants who demonstrated a favorable response after an initial 24-week treatment period. Following a subsequent 28-week maintenance or withdrawal phase,…
-
Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension
•
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food and Drug Administration (FDA) has accepted for priority review an indication extension filing for its interleukin blocker Dupixent (dupilumab). The drug is proposed as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD),…
-
Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint
•
Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its RIPK1-targeted small-molecule drug for amyotrophic lateral sclerosis (ALS). The drug, developed in partnership with France-based Sanofi Inc. (NASDAQ: SNY), failed to meet the primary endpoint in the Phase II HIMALAYA study, which assessed the change…
-
Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the fourth quarter and full year of 2023. The company’s global revenues for the 12-month period reached EUR 43.07 billion (USD 47 billion), marking a 5.3% increase year-on-year in constant currency terms. Key drivers of this…
-
Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology firm Graviton Bioscience, securing a right of first negotiation for Graviton’s clinical-stage ROCK2 inhibitor candidates in immunological and metabolic syndrome indications. Graviton’s lead program, GV101, is a potential best-in-class ROCK2 inhibitor capable of crossing the…
-
EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma
•
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has endorsed Bristol Myers Squibb’s (BMS; NYSE: BMY) CAR-T cell therapy, Abecma (idecabtagene vicleucel), for the treatment of relapsed and refractory multiple myeloma (r/r MM) in adults who have undergone at least two prior therapies.…
-
Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients
•
The US Food and Drug Administration (FDA) has concluded a priority review and granted approval to Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) for their interleukin blocker Dupixent (dupilumab) as a treatment for eosinophilic esophagitis (EoE) in patients aged 1 to 11 years. This indication expansion makes Dupixent the sole…
-
Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced the acquisition of INBRX-101, a promising candidate for rare genetic diseases, from U.S. biotechnology firm Inhibrx (NASDAQ: INBX). INBRX-101, currently in Phase II trials for alpha-1 antitrypsin deficiency (AATD), is a recombinant human AAT-Fc fusion protein designed to restore serum AAT activity,…
-
Sanofi’s Dupixent Receives FDA Label Update for Atopic Dermatitis Patients with Hand or Foot Involvement
•
Sanofi (NASDAQ: SNY) has been granted authorization by the US Food and Drug Administration (FDA) to update the label of Dupixent (dupilumab) to include efficacy and safety data for patients aged 12 and older with atopic dermatitis that involves uncontrolled moderate-to-severe hand or foot symptoms. The data from a late-stage…
-
Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies
•
Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company has no plans to develop a competing product in the GLP-1 drug market, dominated by Novo Nordisk (CPH: NOVO-B) and Eli Lilly (NYSE: LLY), despite significant demand. However, Houman Ashrafian, head of R&D, indicated that…
-
AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA
•
AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have announced that they have received marketing approval from the National Medical Products Administration (NMPA) for their drug Beyfortus (nirsevimab). The antibody is now approved for use in preventing lower respiratory tract infections caused by respiratory…
-
Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China, has entered into a comprehensive partnership with the French pharmaceutical giant Sanofi (NASDAQ: SNY). The collaboration aims to address major disease areas on a nationwide scale, establishing an end-to-end value chain system that spans from…
-
Sanofi Gains NMPA Approval for Innovative Rosuvastatin and Ezetimibe Combination Therapy
•
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its fixed-dose combination tablets of rosuvastatin and ezetimibe. This therapy is indicated for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). This product marks the first…
-
Sanofi Halts Development of Tusamitamab Ravtansine After Missed Trial Endpoints
•
Sanofi (NASDAQ: SNY) has announced the discontinuation of its antibody-drug conjugate (ADC) tusamitamab ravtansine following disappointing results from a Phase III trial in metastatic non-squamous (NSq) non-small cell lung cancer (NSCLC) patients with high CEACAM5 expression. The trial did not meet its dual primary endpoints, as indicated by an interim…
-
Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug design company Exscientia (NASDAQ: EXAI) by in-licensing a program in an undisclosed therapeutic area. This move builds on a 2022 agreement aimed at developing up to 15 novel small-molecule candidates across oncology and immunology. The…
-
Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma
•
Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors from France-based Innate Pharma (NASDAQ: IPHA), as per an agreement reached in 2022. Sanofi will pay an initial fee of EUR 15 million (USD 16.4 million) and is committed to potential milestone payments of up…
-
EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment
•
Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on Sanofi’s (NASDAQ: SNY) Fexinidazole Winthrop (fexinidazole) as a 10-day treatment for acute sleeping sickness caused by Trypanosoma brucei (T.b.) rhodesiense in both adults and children. The EMA is…
-
Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s first and only ROCK2 inhibitor for the treatment of chronic graft-versus-host disease (cGVHD), has received marketing approval in China. Clinical data indicates that Rezurock achieves a 75% overall response rate (ORR), a 75% 6-month failure-free…
-
Sanofi Abandons MZE001 Licensing Deal Following FTC Intervention Over Pompe Disease Monopoly Concerns
•
Sanofi (NASDAQ: SNY) has withdrawn from an agreement announced earlier this year to in-license the glycogen synthase 1 (GYS1) inhibitor MZE001 from Maze Therapeutics, following an administrative complaint by the Federal Trade Commission (FTC), the US antitrust agency. The FTC sought a temporary restraining order and preliminary injunction in federal…
-
Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt
•
Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally manufacture and supply its leading anticoagulant, Clexane (enoxaparin). The technology transfer agreement is aimed at enabling the French pharmaceutical giant to navigate “changing market dynamics,” as stated in a press release. Production of the medication…
-
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
•
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues…
-
Dupixent Trial Success Reinforces Potential in Moderate-to-Severe COPD Treatment
•
Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial for their interleukin blocker Dupixent (dupilumab) has successfully met its primary endpoint during an interim analysis. The trial demonstrated a significant reduction in exacerbations over 52 weeks in patients with chronic obstructive pulmonary disease (COPD)…
-
Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals
•
BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, have announced a significant agreement. Sanofi has reacquired the exclusive development and commercialization rights to Rezurock (belumosudil), the world’s first ROCK2 inhibitor, in mainland China from BK Pharmaceuticals Ltd and BioNova…
-
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
•
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a net sales decrease of -4.1% year-on-year (YOY) but an increase of 3.2% in constant currency terms, reaching EUR 11.96 billion (USD 12.64 billion). Despite maintaining the forecast for 2023 earnings per share (EPS) growth, Sanofi…
-
Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development
•
Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the joint development and commercialization of Teva’s Phase II drug candidate, TEV’574, targeting inflammatory bowel diseases (IBD). This investigational molecule is designed as a potential best-in-class anti-TL1A therapy aimed at treating ulcerative colitis (UC) and Crohn’s…
-
Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease
•
Sanofi’s (NASDAQ: SNY) next-generation enzyme replacement therapy (ERT), Nexviazyme (avalglucosidase alfa), has received marketing approval from the National Medical Products Administration (NMPA) as a long-term treatment for Pompe disease. This marks Sanofi’s second drug approved for Pompe disease in China, following the approval of Myozyme (alglucosidase alfa) in October 2015.…
-
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic partnership with Sanofi (NASDAQ: SNY) to develop and commercialize a groundbreaking 9-valent vaccine targeting extraintestinal pathogenic Escherichia coli (ExPEC). Currently in late-stage trials, this vaccine aims to prevent invasive E. coli disease (IED) in adults…
-
Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its first-in-class drug Altuviiio (Fc-VWF-XTEN fusion protein). This new treatment is indicated for controlling the bleeding tendency in patients with hemophilia A, a genetic disorder that…
-
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
•
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval from the National Medical Products Administration (NMPA) in China for its drug Dupixent (dupilumab), which is now approved to treat prurigo nodosa (PN) in adults. This makes Dupixent the first and only drug approved for…
-
Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products
•
UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic acquisition of four central nervous system (CNS) products from French pharmaceutical giant Sanofi (NASDAQ: SNY). This move signifies Pharmanovia’s commitment to enhancing its neurology offerings and aligns with Sanofi’s strategy to divest its Consumer Health…
